openPR Logo
Press release

Diffuse Large B-Cell Lymphoma Market – Global Industry Demand, Growth, Prize and Business Forecast by 2025

09-15-2017 09:00 AM CET | Health & Medicine

Press release from: TMR Research

Diffuse Large B-Cell Lymphoma Market – Global Industry Demand, Growth, Prize and Business Forecast by 2025

Global Diffuse Large B-cell Lymphoma Market: Snapshot

Lymphoma is a type of cancer affecting the human lymphatic system, a part of our immune system. The development of lymphoma begins when a type of white bold cell, lymphocytes commence to divide in an uncontrolled manner. Although there are two chief kinds of lymphocytes, T lymphocytes and B lymphocytes, B cells tend to be responsible for most lymphomas. Diffuse large B-cell lymphoma (DLBCL) develop from B cells that are abnormal, larger sized cells which are different from healthy, normal B cells. These abnormal cells spread out diffusely all over the tumor, wiping out the lymph node’s normal structure.

More than 4,800 people in the U.K. are diagnosed with diffuse large B-cell lymphoma every year, according to the U.K. Lymphoma Association. The disease can occur at any age, affecting children as well. However, the aged population is at a higher risk of developing diffuse large B-cell lymphoma. Several patients initially notice painless lumps, usually in their neck, groin, or armpit. Apart from this, loss of appetite, itching, and fatigue are also some other common symptoms.

Request Sample Copy of the Report @ www.tmrresearch.com/sample/sample?flag=B&rep_id=494

The continuous development of novel treatments and drugs for treating diffuse large B-cell lymphoma via research and development is assisting the growth of the global market for diffuse large B-cell lymphoma. For instance, in May 2017, it was announced that a rare sub-type of DLBCL, primary mediastinal B-cell lymphoma, can be treated through the use of pembrolizumab, a PD-1 inhibitor. An evaluation of 18 participants with diffuse large B-cell lymphoma under KEYNOTE 013 revealed the safety and efficacy of pembrolizumab.

Diffuse Large B-Cell Lymphoma Market: Overview

With a noticeable rise in the prevalence of diffuse large B-cell lymphoma (DLBCL), the market for DLBCL market is witnessing strong growth across the world. Analysts expect the trend to remain so over the next few years, owing to the increasing number of elderly people, the most prone to DLBCL segment of the overall population.

Request TOC of the Report @ www.tmrresearch.com/sample/sample?flag=T&rep_id=494

Diffuse large B-cell lymphoma (DLBCL) is the most common form of non hodgkin lymphoma (NHL) and is the main reason behind more than 30% of the newly diagnosed cancer cases in the U.S. alone. The prevalence of this disease is increasing at an alarming rate, which is likely to fuel the demand for DLBCL treatments substantially in the near future, leading to a considerable market growth.

This research report offers a detailed evaluation of the global market for DLBCL on the basis of its current and historical performance. The prominent trends, growth drivers, challenges, opportunities, and the future prospects of this market have also been examined thoroughly while conducting this study. The main objective of this study is to assist the market participants in gaining a clear and deep insight into this market.

Diffuse Large B-Cell Lymphoma Market: Trends and Opportunities

The increasing incidence of DLBCL has fueled the demand for efficient therapies for its treatment across the world. With the ever-rising global geriatric population, the scenario is likely to remain more or less similar over the forthcoming years. In addition, the presence of a robust last stage pipeline of drugs ready for clinical trials and the increasing expenditure on healthcare are expected to boost this market tremendously in the years to come.

Request Discount of the Report @ www.tmrresearch.com/sample/sample?flag=D&rep_id=494

At present, the most efficient treatment for DLBCL available across the world is combination therapy that includes chemotherapy and monoclonal antibody-based drug Rituxan (rituximab). However, the development of other drugs is also taking place at a swift pace, with many of them being in various late-stage clinical trials. Alisertib (MLN8237), Bortezomib (Velcade), Brentuximab vedotin (Adcetris), Everolimus (Afinitor), Lenalidomide (Revlimid), Panobinostat, and Vorinostat (Zolinza) are some of the key pipelined projects, approval of which will gain advantages for this market in the forthcoming years.

Diffuse Large B-Cell Lymphoma Market: Geographical Analysis

North America, followed by Europe, has surfaced as the leading contributor to the global market for DLBCL, thanks to the high prevalence of DLBCL, rising awareness level of people, and their increased disposable income. However, Asia Pacific is likely to emerge as the most promising regional market in the coming years. The strengthening economy and the improving healthcare infrastructure in this region are expected to act as the key driving force behind the growth of the Asia Pacific DLBCL market.

Diffuse Large B-Cell Lymphoma Market: Companies Mentioned in the Report

Some of the major players operating in this market are Amgen, Inc., AstraZeneca plc, Astellas Pharma, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Gilead Sciences, Inc., Genentech, Inc., Infinity Pharmaceuticals, Inc., MedImmune, LLC, Merck & Co., Inc., Novartis AG and Sanofi.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Our savvy custom-built reports span a gamut of industries such as pharmaceuticals, chemicals and metals, food and beverages, and technology and media, among others. With actionable insights uncovered through in-depth research of the market, we try to bring about game-changing success for our clients.

Contact:

Rohit Bhisey
Head - Internet Marketing
Tel: +1-415-520-1050
Email: sales@tmrresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Diffuse Large B-Cell Lymphoma Market – Global Industry Demand, Growth, Prize and Business Forecast by 2025 here

News-ID: 718800 • Views: 179

More Releases from TMR Research

Overview On Upcoming Need 2025: Dyslipidemia drugs Market |AstraZeneca, Aegerion …
Global Dyslipidemia Drugs Market: Snapshot Dyslipidemia is a cardiovascular condition comprising of changes in the amount of lipids in the blood. Dyslipidemia can show as either absence of or abundance of lipids in blood; hyperlipidemia, the state of having overabundance lipids in the blood, is probably going to hold the major share in the global dyslipidemia drugs market in the within the forecast period. Various issues related with dietary habits and
Intravenous Iron Drugs Market 2017-2025 | Fresenius Medical Care AG & Co. KGaA, …
Intravenous Iron Drugs Market: Snapshot Iron is one of the most significant minerals required for the correct working of human bodies. Iron insufficiency prompts various medical problems, for example, anemia and could have a grave and direct association with the several of hospitalizations and deaths. The global market for intravenous drugs is foreseen to display a solid CAGR over the report's forecast period attributable to the rising pervasiveness of anemia cases
E-Clinical Solution Software Market Detailed Global Analysis and Forecast 2017-2 …
Global E-Clinical Solution Software Market: Snapshot The current advances in the healthcare industry is witnessing an increasingly connected and technology-advanced operational infrastructure. This has led to it becoming one of the largest producers of sensitive and personal data about the numerous patients it caters to daily. Hospitals, clinics, laboratories, insurance companies and other medical networks are swamped with gargantuan amount of patient information. This has generated an urgent need to create
Nuclear Decommissioning Services Market 2017-2025 | Babcock International Group …
Global Nuclear Decommissioning Services Market: Snapshot The demand in the global market for nuclear decommissioning market is driven by a number of factors including accidents and rising political pressure for pre-closure, stringent regulations since Fukushima accident, public and government support for decommissioning of nuclear reactors, worldwide shut down of older reactors, and increase in the use of renewable energy. On the other hand, stringent regulatory standards, reliability of nuclear power, difficulty

All 26063 Releases


More Releases for DLBCL

Diffuse Large B-Cell Lymphoma Market - Upcoming Development 2025 | Genentech, In …
Global Diffuse Large B-cell Lymphoma Market: Snapshot Lymphoma is a type of cancer affecting the human lymphatic system, a part of our immune system. The development of lymphoma begins when a type of white bold cell, lymphocytes commence to divide in an uncontrolled manner. Although there are two chief kinds of lymphocytes, T lymphocytes and B lymphocytes, B cells tend to be responsible for most lymphomas. Diffuse large B-cell lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2022 Vendors, Driving …
The research report shows the continuous growth over the years in Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market with market size, growth rate, driving & trending factors, market trends, opportunities and threats. Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics market report provides top vendors, geographical regions, revenue, types, application, end users. Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics market 2018-2022 provides market landscape, market sizing, buyers, suppliers, new entrants, market share, revenue, consumption,
Diffuse Large B-Cell Lymphoma Market trends and dynamics 2017 - 2025 : Genentech …
Global Diffuse Large B-cell Lymphoma Market: Snapshot Lymphoma is a type of cancer affecting the human lymphatic system, a part of our immune system. The development of lymphoma begins when a type of white bold cell, lymphocytes commence to divide in an uncontrolled manner. Although there are two chief kinds of lymphocytes, T lymphocytes and B lymphocytes, B cells tend to be responsible for most lymphomas. Diffuse large B-cell lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma Market Trends and Opportunities 2017 - 2025 : Infi …
Global Diffuse Large B-cell Lymphoma Market: Snapshot Lymphoma is a type of cancer affecting the human lymphatic system, a part of our immune system. The development of lymphoma begins when a type of white bold cell, lymphocytes commence to divide in an uncontrolled manner. Although there are two chief kinds of lymphocytes, T lymphocytes and B lymphocytes, B cells tend to be responsible for most lymphomas. Diffuse large B-cell lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma Market is on Higher Demand 2017 - 2025
Global Diffuse Large B-cell Lymphoma Market: Snapshot Lymphoma is a type of cancer affecting the human lymphatic system, a part of our immune system. The development of lymphoma begins when a type of white bold cell, lymphocytes commence to divide in an uncontrolled manner. Although there are two chief kinds of lymphocytes, T lymphocytes and B lymphocytes, B cells tend to be responsible for most lymphomas. Diffuse large B-cell lymphoma (DLBCL)
DLBCL receives FDA orphan drug designation for eFT508
US Food and Drug Administration has announced orphan drug designation to eFT508, a highly selective inhibitor of MNK1 and MNK2 for the treatment of diffuse large B-cell lymphoma. The drug is developed by eFFECTOR Therapeutics. The company has initiated to evaluate the safety, pharmacokinetics, pharmacodynamics and antitumor activity of the agent in patients with B-cell hematologic malignancies. The company also is conducting a phase 1/phase 2 dose-escalation trial of eFT508